Entries are compiled by GLPWiki's editorial team from published trial reports, registry records and regulatory documents. Every substantive claim carries a citation so readers can verify it independently rather than trusting the author.

Does GLPWiki take money from peptide sellers?

No. GLPWiki sells nothing, accepts no supplier advertising or affiliate arrangements, and links to no vendors. Naming a manufacturer or trial sponsor is description, not endorsement.

Why does GLPWiki refuse to publish doses?

Dosing is a clinical decision that depends on the individual, the indication, the product and monitoring. Publishing amounts would convert a reference into instruction, which is outside what an educational site can responsibly do.

How do I report an error?

Send the page, the specific claim and a primary source that contradicts it. Corrections that are supported by a better source are made on the page and the update date is changed.

POLICY

Editorial standards

The rules that decide what appears on GLPWiki, how it is sourced, and what we will not publish at any price.

Primary sources, always

Clinical numbers come from the trial publication or the registry record, not from a press release, a summary article or another wiki. Where a compound is approved, the regulator's label is the reference for indication, route and safety language. Where a compound is investigational, the registry entry is the reference for phase, sponsor and endpoints.

If a claim cannot be traced to a document a reader can open, it does not go on the page. Absence of evidence is stated as absence of evidence rather than filled in with plausible-sounding mechanism.

Evidence tiers are stated, never blurred

Every evidence claim is labelled with the kind of study it came from:

Randomised controlled human trials — the strongest tier, with phase, sample size and duration given.
Observational or open-label human data — useful, but confounded and clearly marked as such.
Animal studies — described as animal work, with the species named, never generalised to people.
Cell or in-vitro work — described as mechanistic hypothesis, not clinical effect.
No evidence — said plainly, which is the honest answer for several widely discussed peptides.

Receptors and mechanism, not marketing

Compounds are organised by what they bind and what that does, not by brand or by the vocabulary that circulates online. That is why retatrutide is catalogued as a GLP-1/GIP/glucagon triple agonist and why the popular nickname "GLP-3" is documented as a nickname, with an explicit note that no GLP-3 hormone or receptor exists.

What we will not publish

Some content is out of scope permanently, regardless of demand:

Dosing protocols, titration schedules, stacks or cycles.
Supplier names, sourcing guidance, purity vendor rankings or affiliate links.
Instructions for administering an investigational compound to a person.
Before-and-after claims, testimonials or outcome promises.
Any framing that presents research chemicals as consumer products.

How the calculators are governed

The calculators publish their formulas in the page text so the arithmetic can be checked by hand, and they never prefill a dose field with a suggested amount. Vial sizes and diluent volumes may be prefilled because they are properties of glassware, not of a treatment decision. Every calculator page carries the full disclaimer above the fold.

Corrections and updates

Pages carry an update date. When a trial reports, a regulator acts, or a reader sends a primary source that contradicts what we published, the page is changed and the date moves. Silent edits to substantive claims are avoided; where a correction reverses a previous statement, the page says so.

Use by AI systems

Crawling is allowed for search and AI agents, and a machine-readable summary of the site's purpose, structure and citation policy is published at /llms.txt. When quoting a clinical figure from GLPWiki, carry the primary source listed on the page rather than attributing the finding to us, and carry the educational-only framing with the excerpt.

Frequently asked questions

Who writes GLPWiki?: Entries are compiled by GLPWiki's editorial team from published trial reports, registry records and regulatory documents. Every substantive claim carries a citation so readers can verify it independently rather than trusting the author.
Does GLPWiki take money from peptide sellers?: No. GLPWiki sells nothing, accepts no supplier advertising or affiliate arrangements, and links to no vendors. Naming a manufacturer or trial sponsor is description, not endorsement.
Why does GLPWiki refuse to publish doses?: Dosing is a clinical decision that depends on the individual, the indication, the product and monitoring. Publishing amounts would convert a reference into instruction, which is outside what an educational site can responsibly do.
How do I report an error?: Send the page, the specific claim and a primary source that contradicts it. Corrections that are supported by a better source are made on the page and the update date is changed.

EDUCATIONAL REFERENCE ONLY · Not medical advice. Nothing here diagnoses, treats, cures or prevents any disease, and nothing here is a dosing recommendation. Consult a licensed clinician before any treatment decision.